STERIS stock has delivered an 11.4% total return over the past five years. At around US$231.78 per share it now screens as roughly in line with its Discounted Cash Flow (DCF) intrinsic value, while earnings-based multiples point to a richer price tag. For investors, the puzzle is that the DCF view suggests STERIS is fairly valued on cash flow assumptions, while the broader valuation checks and multiples imply the stock is not especially cheap.

• Over five years, STERIS has produced an 11.4% total return, which is a steady outcome rather than a dramatic long term re rating.
• The planned US$600 million Center of Excellence in North Carolina can support long term growth in sterilization and disinfection products, but the associated restructuring and capital spend may weigh on near term cash flows and valuation flexibility.
• STERIS passes only 1 of 6 valuation checks, which means the stock currently leans expensive on the wider assessment even if the DCF view is closer to fair value.

The stock's next move may depend on whether STERIS can grow into its current price so that both the intrinsic value view and the market multiples eventually tell a more consistent story.

Does STERIS Look Fairly Valued on Cash Flow?

The Discounted Cash Flow (DCF) approach values STERIS based on the cash it is expected to generate for shareholders. For STERIS, the model uses latest twelve month free cash flow of about US$946.7 million and assumes a growing but relatively steady cash flow profile rather than aggressive expansion or sharp decline. On that basis, the DCF model points to an estimated intrinsic value of about $240 per share.

Compared with the recent share price near $231.78, this implies the stock trades at roughly a 3.5% discount to the DCF estimate, which is close enough to treat as within a fair value band. The planned US$600 million Center of Excellence in North Carolina is a large commitment, and the associated restructuring helps explain why the market may be hesitant to price STERIS much above the current DCF value.

On this cash flow view, STERIS stock appears to be roughly fairly valued today.

STERIS is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Has STERIS Run Too Far on Earnings?

The P/E ratio is a useful lens for STERIS because earnings remain a key driver of how the market prices established healthcare equipment companies. STERIS currently trades on a P/E of about 28.9x, which sits slightly above the medical equipment industry average of roughly 27.5x and also above the peer group average near 22.9x.

The tailored fair P/E for STERIS, which reflects its profile relative to peers, is estimated at about 25.4x. That is a few turns lower than the current multiple and points to the stock being priced at a premium to what this framework suggests is reasonable for its earnings. The gap is not extreme, but it does indicate that investors are already paying up for STERIS relative to both the sector and this fair value marker.

On this earnings multiple view, STERIS stock currently appears overvalued.

The STERIS Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take the valuation puzzle around STERIS' DCF and earnings multiples and turn it into clear, scenario-style stories about what growth, margins and earnings would need to look like for the stock to be worth materially more or less than today. These narratives sit on the company’s Community page. Rather than focusing on a single multiple or model output, each narrative lays out the key assumptions behind its view so you can track how they stack up as new results arrive.

Share a narrative on STERIS and add your voice to the Simply Wall St community with a focused, number-driven view on whether the planned US$600m Center of Excellence in North Carolina ultimately delivers on its potential. Put your thesis on record today and see how it stands up as new data and results arrive.

Do you think there's more to the story for STERIS? Head over to our Community to see what others are saying!

The Bottom Line

STERIS screens as roughly fairly valued on its Discounted Cash Flow (DCF) intrinsic value estimate, while the earnings multiples still point to an overvalued stock compared with peers. That split mainly comes down to how investors weigh the timing of cash flows and capital spending against current growth expectations and sentiment in the medical equipment group. With broader valuation checks remaining weak, the key question is whether STERIS can deliver enough earnings growth and returns on its planned investments, including the new Center of Excellence, to justify the premium multiple that the market is already paying.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.